Andrew Macann
YOU?
Author Swipe
View article: Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models
Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models Open
Tumour hypoxia promotes poor patient outcomes, with particularly strong evidence for head and neck squamous cell carcinoma (HNSCC). To effectively target hypoxia, therapies require selection biomarkers and preclinical models that can accur…
View article: RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL Open
Introduction: The TROG99.03 represents the only randomised phase III trial of combined modality therapy (CMT) in limited-stage follicular lymphoma 'LSFL', reporting a prolonged progression-free survival (PFS) in the CMT arm (MacManus, JCO,…
View article: Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer
Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer Open
Patient survival from head and neck squamous cell carcinoma (HNSCC), the seventh most common cause of cancer, has not markedly improved in recent years despite the approval of targeted therapies and immunotherapy agents. Precision medicine…
View article: Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models Open
Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activ…
View article: Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma Open
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hyp…
View article: Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy
Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy Open
The results support the hypothesis that humidification can help mitigate mucositis symptom burden. Radiotherapy dosimetric parameters assist in the evaluation of toxicity interventions.
View article: CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL
CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL Open
Aim: Curative-intent involved field radiation therapy (IFRT) is a standard treatment for stage I-II follicular lymphoma (FL). It achieves durable local disease control and can produce life-long remissions. However ≥50% of patients relapse,…